# CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

Source: https://onco.cc/trials/nct06699836/  
OnCo record `nct06699836` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in colorectal cancer, run by CytoDyn, Inc., active and no longer recruiting.

## Summary

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen is a phase 2 interventional study registered as NCT06699836 by CytoDyn, Inc., with 66 participants enrolled, started 2025-06-16 and due to reach its primary completion in 2028-01. Interventions recorded: 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab. Conditions listed: Metastatic Colorectal Cancer (mCRC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06699836
- Phase: 2
- Setting: A Phase Two Study Evaluating Two Doses of Leronlimab (PRO 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)
- Sponsor: CytoDyn, Inc.
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT06699836: https://clinicaltrials.gov/study/NCT06699836

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct06699836.json